[Patient-reported outcome and its application in hematological neoplasm].
作者信息
Jiang Q
机构信息
Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing 100044, China.
出版信息
Zhonghua Xue Ye Xue Za Zhi. 2019 Jul 14;40(7):614-619. doi: 10.3760/cma.j.issn.0253-2727.2019.07.019.
Abstract
摘要
相似文献
1
[Patient-reported outcome and its application in hematological neoplasm].[患者报告结局及其在血液肿瘤中的应用]
Zhonghua Xue Ye Xue Za Zhi. 2019 Jul 14;40(7):614-619. doi: 10.3760/cma.j.issn.0253-2727.2019.07.019.
2
Using patient-reported outcomes to improve survivorship care.利用患者报告的结局来改善生存护理。
Blood. 2020 May 21;135(21):1819-1820. doi: 10.1182/blood.2020005881.
3
Paper and electronic versions of HM-PRO, a novel patient-reported outcome measure for hematology: an equivalence study.HM-PRO 纸质版和电子版，一种新型血液病患者报告结局测量工具：一项等效性研究。
J Comp Eff Res. 2019 May;8(7):523-533. doi: 10.2217/cer-2018-0108. Epub 2019 Apr 30.
4
Patient-Reported Outcomes in Phase 3 Clinical Trials for Blood Cancers: A Systematic Review.血液癌三期临床试验中的病患报告结局：系统性回顾。
JAMA Netw Open. 2024 Jun 3;7(6):e2414425. doi: 10.1001/jamanetworkopen.2024.14425.
5
Donor lymphocyte infusion. An adaptive cellular immunotherapy for treatment of hematological malignancies.供体淋巴细胞输注。一种用于治疗血液系统恶性肿瘤的适应性细胞免疫疗法。
Saudi Med J. 2003 Feb;24(2):138-41.
6
Diagnostic application of FISH to hematological malignancies.荧光原位杂交技术在血液系统恶性肿瘤中的诊断应用。
Cancer Invest. 2003;21(5):807-14. doi: 10.1081/cnv-120023780.
7
Important questions for the malignant hematologist to consider when designing or evaluating a study with patient-reported outcome measures (PROMs).恶性血液病学家在设计或评估患者报告结局测量（PROMs）研究时需要考虑的重要问题。
Eur J Haematol. 2022 Jul;109(1):3-9. doi: 10.1111/ejh.13774. Epub 2022 Apr 29.
8
Patient-Reported Outcomes for Cancer Patients with Hematological Malignancies Undergoing Chimeric Antigen Receptor T Cell Therapy: A Systematic Review.接受嵌合抗原受体 T 细胞治疗的血液恶性肿瘤癌症患者的患者报告结局：系统评价。
Transplant Cell Ther. 2021 May;27(5):390.e1-390.e7. doi: 10.1016/j.jtct.2021.01.003. Epub 2021 Jan 7.
9
Patient-reported distress and problems among elderly patients with hematological malignancy in Korea.韩国老年血液恶性肿瘤患者的报告困扰和问题。
Support Care Cancer. 2022 Nov;30(11):9019-9027. doi: 10.1007/s00520-022-07315-9. Epub 2022 Aug 10.
10
Quality of life and CAR-T cell therapy in children, adolescents, and young adults with haematological malignancies.血液系统恶性肿瘤儿童、青少年和青年的生活质量与嵌合抗原受体T细胞（CAR-T）疗法
Lancet Oncol. 2019 Dec;20(12):1625-1626. doi: 10.1016/S1470-2045(19)30641-2. Epub 2019 Oct 9.
引用本文的文献
1
[Chinese expert consensus on the diagnosis and treatment of chronic graft-versus-host disease (2024)].《慢性移植物抗宿主病诊断与治疗中国专家共识（2024年版）》
Zhonghua Xue Ye Xue Za Zhi. 2024 Aug 14;45(8):713-726. doi: 10.3760/cma.j.cn121090-20240611-00217.
2
[Evaluation of differences in quality of life in patients with chronic graft-versus-host disease].[慢性移植物抗宿主病患者生活质量差异的评估]
Zhonghua Xue Ye Xue Za Zhi. 2024 Jan 14;45(1):54-61. doi: 10.3760/cma.j.cn121090-20231008-00162.
本文引用的文献
1
Patient-reported fatigue prior to treatment is prognostic of survival in patients with acute myeloid leukemia.患者报告的治疗前疲劳是急性髓系白血病患者生存的预后因素。
Oncotarget. 2018 Jul 27;9(58):31244-31252. doi: 10.18632/oncotarget.25787.
2
Achieving optimal response at 12 months is associated with a better health-related quality of life in patients with chronic myeloid leukemia: a prospective, longitudinal, single center study.在 12 个月时达到最佳反应与慢性髓性白血病患者更好的健康相关生活质量相关：一项前瞻性、纵向、单中心研究。
BMC Cancer. 2018 Aug 3;18(1):782. doi: 10.1186/s12885-018-4699-5.
3
Patients' and hematologists' concerns regarding tyrosine kinase-inhibitor therapy in chronic myeloid leukemia.患者及血液科医生对慢性髓性白血病酪氨酸激酶抑制剂治疗的担忧。
J Cancer Res Clin Oncol. 2018 Apr;144(4):735-741. doi: 10.1007/s00432-018-2594-8. Epub 2018 Jan 29.
4
Higher out-of-pocket expenses for tyrosine kinase-inhibitor therapy is associated with worse health-related quality-of-life in persons with chronic myeloid leukemia.酪氨酸激酶抑制剂治疗的自付费用较高与慢性髓性白血病患者健康相关生活质量较差有关。
J Cancer Res Clin Oncol. 2017 Dec;143(12):2619-2630. doi: 10.1007/s00432-017-2517-0. Epub 2017 Sep 11.
5
Patient-reported outcomes in hematology: is it time to focus more on them in clinical trials and hematology practice?血液学中的患者报告结局：在临床试验和血液学实践中是否更应该关注它们？
Blood. 2017 Aug 17;130(7):859-866. doi: 10.1182/blood-2017-03-737403. Epub 2017 Jul 10.
6
Variables associated with patient-reported outcomes in persons with chronic myeloid leukemia receiving tyrosine kinase-inhibitor therapy.接受酪氨酸激酶抑制剂治疗的慢性髓性白血病患者中与患者报告结局相关的变量。
J Cancer Res Clin Oncol. 2017 Jun;143(6):1013-1022. doi: 10.1007/s00432-017-2353-2. Epub 2017 Mar 1.
7
Health-related quality of life in long-term survivors of acute lymphoblastic leukemia in childhood and adolescence.儿童和青少年急性淋巴细胞白血病长期幸存者的健康相关生活质量
Qual Life Res. 2017 May;26(5):1371-1377. doi: 10.1007/s11136-016-1462-8. Epub 2016 Nov 24.
8
The efficacy and safety of continued hydroxycarbamide therapy versus switching to ruxolitinib in patients with polycythaemia vera: a randomized, double-blind, double-dummy, symptom study (RELIEF).真性红细胞增多症患者继续使用羟基脲治疗与改用鲁索替尼治疗的疗效和安全性：一项随机、双盲、双模拟、症状研究（RELIEF）。
Br J Haematol. 2017 Jan;176(1):76-85. doi: 10.1111/bjh.14382. Epub 2016 Nov 8.
9
Prevalence of symptoms in patients with multiple myeloma: a systematic review and meta-analysis.多发性骨髓瘤患者症状的患病率：一项系统评价和荟萃分析
Eur J Haematol. 2016 Nov;97(5):416-429. doi: 10.1111/ejh.12790. Epub 2016 Sep 6.
10
Health-related quality of life and patient-reported outcomes of ofatumumab plus chlorambucil versus chlorambucil monotherapy in the COMPLEMENT 1 trial of patients with previously untreated CLL.在COMPLEMENT 1试验中，奥法木单抗联合苯丁酸氮芥与苯丁酸氮芥单药治疗既往未治疗的慢性淋巴细胞白血病患者的健康相关生活质量及患者报告结局。
Acta Oncol. 2016 Sep-Oct;55(9-10):1115-1120. doi: 10.1080/0284186X.2016.1205217. Epub 2016 Aug 5.
Zotero 插件